ADPT

SEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 12

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 451,463

Underlying: Common Stock · 11,881 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F7 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 11

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 180,603

Underlying: Common Stock · 14,722 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F6 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 583,911

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.11 to $16.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 590,429

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $16.10, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 614,852

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President and COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 602,971

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.

SEC source: 0001229765-26-000001 · primary_doc.xml · derivative · entry 3

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 48,044 shares

Expires 2034-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001229765-26-000001 · primary_doc.xml · nonDerivative · entry 2

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,394

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $15.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001229765-26-000001 · primary_doc.xml · nonDerivative · entry 1

GRIFFIN MICHELLE RENEE · CIK 0001229765 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,438

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.

SEC source: 0001780649-26-000003 · primary_doc.xml · nonDerivative · entry 2

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,987,330

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.51 to $16.18, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780851-26-000003 · primary_doc.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,169,524

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.57 to $15.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780649-26-000003 · primary_doc.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,276,354

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.83 to $16.20, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780662-26-000002 · primary_doc.xml · derivative · entry 3

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,146

Underlying: Common Stock · 2,145 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780662-26-000002 · primary_doc.xml · nonDerivative · entry 2

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 216,637

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

SEC source: 0001780662-26-000002 · primary_doc.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 218,782

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

SEC source: 0001780851-26-000002 · primary_doc.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,179,524

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.56 to $19.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780649-26-000002 · primary_doc.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,459,245

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780851-26-000002 · primary_doc.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,187,644

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.26 to $18.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780662-26-000001 · primary_doc.xml · derivative · entry 3

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,291

Underlying: Common Stock · 4,290 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780662-26-000001 · primary_doc.xml · nonDerivative · entry 2

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 216,637

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

SEC source: 0001780662-26-000001 · primary_doc.xml · nonDerivative · entry 1

PISKEL KYLE · CIK 0001780662 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 220,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.

SEC source: 0001780660-26-000003 · primary_doc.xml · derivative · entry 10

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 90,641

Underlying: Common Stock · 14,215 shares

Expires 2034-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000003 · primary_doc.xml · derivative · entry 9

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,074

Underlying: Common Stock · 21,002 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000003 · primary_doc.xml · derivative · entry 8

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,615

Underlying: Common Stock · 7,723 shares

Expires 2032-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000003 · primary_doc.xml · derivative · entry 7

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,500

Underlying: Common Stock · 36,650 shares

Expires 2029-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F2 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 5

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 315,978

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 4

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 395,568

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 381,353

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 360,351

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 352,628

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780851-26-000001 · primary_doc.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,222,312

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780649-26-000001 · primary_doc.xml · nonDerivative · entry 1

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,584,243

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.

F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.31 to $15.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780660-26-000001 · primary_doc.xml · derivative · entry 4

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,856

Underlying: Common Stock · 3,125 shares

Expires 2034-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000001 · primary_doc.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 315,978

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F2 · price: The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.77 to $16.40, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780660-26-000001 · primary_doc.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 319,103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-25-000003 · primary_doc.xml · derivative · entry 8

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,075

Underlying: Common Stock · 1,100 shares

Expires 2034-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-25-000003 · primary_doc.xml · derivative · entry 7

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,982

Underlying: Common Stock · 2,194 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-25-000003 · primary_doc.xml · derivative · entry 6

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,150

Underlying: Common Stock · 1,100 shares

Expires 2029-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780660-25-000003 · primary_doc.xml · nonDerivative · entry 4

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 315,978

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $17.49 to $17.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780660-25-000003 · primary_doc.xml · nonDerivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 320,372

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-25-000003 · primary_doc.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 319,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-25-000003 · primary_doc.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 317,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-26-000002 · primary_doc.xml · derivative · entry 8

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,981

Underlying: Common Stock · 2,194 shares

Expires 2034-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000002 · primary_doc.xml · derivative · entry 7

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,076

Underlying: Common Stock · 1,100 shares

Expires 2033-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001780660-26-000002 · primary_doc.xml · derivative · entry 6

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,150

Underlying: Common Stock · 1,100 shares

Expires 2029-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F3 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001780660-26-000002 · primary_doc.xml · nonDerivative · entry 4

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 315,978

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F2 · price: The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $17.49 to $17.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001780660-26-000002 · primary_doc.xml · nonDerivative · entry 3

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 320,372

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-26-000002 · primary_doc.xml · nonDerivative · entry 2

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 318,178

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-26-000002 · primary_doc.xml · nonDerivative · entry 1

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 317,078

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

SEC source: 0001780660-25-000002 · primary_doc.xml · derivative · entry 8

LO FRANCIS · CIK 0001780660 · Chief People Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,175

Underlying: Common Stock · 39,849 shares

Expires 2034-03-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.